TGF-beta receptor II + CD40 soluble receptor

The "TGF-beta receptor II + CD40 soluble receptor" refers to a bifunctional recombinant fusion protein designed to simultaneously inhibit two major signaling pathways involved in autoimmunity and fibrosis. The molecule typically consists of the extracellular domains (ECDs) of the human TGF-beta receptor II (TGFBR2) and the CD40 receptor, often linked via an immunoglobulin Fc domain to enhance stability and half-life. Functionally, the TGFBR2 component acts as a "trap" for soluble TGF-beta (primarily TGF-β1 and TGF-β3), while the soluble CD40 component acts as a trap for the CD40 ligand (CD40L or CD154). By neutralizing these ligands, the fusion protein prevents the pro-inflammatory and pro-fibrotic effects of TGF-beta as well as the T-cell/B-cell costimulatory interactions mediated by the CD40-CD40L axis. This dual-action mechanism has been primarily investigated in preclinical research for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis, where it has shown efficacy in reducing autoantibody production and renal inflammation.

Other names

TGF-beta receptor II-Fc-CD40 soluble receptor fusion proteinsoluble TGF-beta receptor II and soluble CD40 fusion proteinsTGFBR2-sCD40 fusion proteinsTGFBR-2-sCD40 fusion proteinsTGFBR 2-sCD40 fusion protein